Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume 29, Issue 11, Pages 925-934
Publisher
Springer Nature
Online
2012-10-27
DOI
10.1007/s12325-012-0060-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer
- (2012) Yan Feng et al. Journal of Thoracic Oncology
- The Role of External Beam Radiation and Targeted Therapy in Thyroid Cancer
- (2012) James Brierley et al. SEMINARS IN RADIATION ONCOLOGY
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification
- (2011) Caterina Mian et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- High Prevalence ofRASMutations inRET-Negative Sporadic Medullary Thyroid Carcinomas
- (2011) Margarida M. Moura et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Bruce G. Robinson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant external beam radiation for medullary thyroid carcinoma
- (2010) Steve R. Martinez et al. JOURNAL OF SURGICAL ONCOLOGY
- Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma
- (2010) Clarissa Capp et al. THYROID
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- RETgenotypes in sporadic medullary thyroid cancer: studies in a large Italian series
- (2008) Laura Fugazzola et al. CLINICAL ENDOCRINOLOGY
- Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma
- (2008) Maria João Bugalho et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study
- (2007) Rossella Elisei et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- New therapeutic approaches to treat medullary thyroid carcinoma
- (2007) Martin Schlumberger et al. Nature clinical practice. Endocrinology & metabolism
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now